Chemistry & Industry: March 2006
Nova BioGenetics, a US antimicrobial company, announces an update from the Company's CEO. During the past six months, the Company has been heavily involved in a series of joint trials with major global manufacturing companies. We have been working in various industries and have tested a number of markets worldwide. Key areas where we have been particularly active include: construction, remediation, textiles, marine, paints and coatings. Details involving a long-term existing agreement between Nova, Palmer Holland, and a global leader in the Construction Industry are expected to be released in the near future.
As a direct result of our close working relationship with market leaders across a range of industries, we have been able to respond to their specific requirements by acquiring the rights to a new, uniquely powerful antimicrobial chemistry. This acquisition enhances Nova's existing suite of EPA approved registered products. The versatility and cost-effectiveness of this ground-breaking technology opens up many global business opportunities for our customers and alliance partners. That, in turn, provides the bedrock for the strong growth now anticipated during the next stage of the Company's development.